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Abstract
The low-density lipoprotein receptor-related protein-1 (LRP1) has a dual role in themetabolism of the amyloid precursor protein (APP).
In cellular models, LRP1 enhances amyloid-β (Aβ) generation via APP internalization and thus its amyloidogenic processing.
However, conditional knock-out studies in mice define LRP1 as an important mediator for the clearance of extracellular Aβ from
brain via cellular degradation or transcytosis across the blood-brain barrier (BBB). In order to analyze the net effect of LRP1 on
production and clearance of Aβ in vivo, we crossed mice with impaired LRP1 function with a mouse model of Alzheimer’s disease
(AD). Analysis of Aβmetabolism showed that, despite reduced Aβ clearance due to LRP1 inactivation in vivo, less Aβwas found in
cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Further analysis of APP metabolism revealed that impairment of LRP1
in vivo shiftedAPP processing from theAβ-generating amyloidogenic cleavage by beta-secretase to the non-amyloidogenic processing
by alpha-secretase as shown by a decrease in extracellular Aβ and an increase of solubleAPP-α (sAPP-α). This shift inAPP processing
resulted in overall lowerAβ levels and a reduction in plaque burden.Here, we present for the first time clear in vivo evidence that global
impairment of LRP1’s endocytosis function favors non-amyloidogenic processing of APP due to its reduced internalization and
subsequently, reduced amyloidogenic processing. By inactivation of LRP1, the inhibitory effect on Aβ generation overrules the
simultaneous impaired Aβ clearance, resulting in less extracellular Aβ and reduced plaque deposition in a mouse model of AD.
Keywords Alzheimer’s disease . Animal model . APP . LRP1 . APPmetabolism . Aβ clearance
Introduction
One of the hallmarks of Alzheimer’s disease (AD) pathogen-
esis is the accumulation of amyloid-β (Aβ) in the brain. It has
been shown that this Aβ accumulation is the result of a dis-
turbed balance of Aβ generation from its precursor APP and
its subsequent clearance. In sporadic or the common late-onset
AD, impaired clearance of Aβ is apparently predominantly
responsible for its accumulation rather than Aβ overproduc-
tion [1]. To date, several mechanisms in the brain have been
identified that are involved in the clearance of extracellular
Aβ from brain interstitial fluid (ISF) and cerebrospinal fluid
(CSF). These include cellular uptake followed by intracellular
degradation by neurons, microglia, pericytes and astrocytes,
extracellular degradation by enzymes in the ISF, efflux into
the periphery by blood-brain barrier (BBB) clearance, and ISF
bulk-flow clearance to the CSF sink or perivascular spaces
followed by degradation or drainage into the circulatory or
lymphatic system ([2, 3], reviewed in [4]). The low-density
lipoprotein receptor-related protein-1 (LRP1) plays a pivotal
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role in Aβ clearance (reviewed in [5]) by mediating receptor-
mediated Aβ uptake and degradation in astrocytes, neurons
and cerebrovascular smooth muscle cells [6–8], or a concerted
Aβ transcytosis together with ABCB1/P-glycoprotein (P-gp)
across the BBB [9–12]. In addition, cellular models have
shown that LRP1 is also a modulator of APP processing driv-
ing Aβ generation via interactions between the intracellular
and extracellular domains of both transmembrane proteins
LRP1 and APP [13–18]. These seemingly opposing roles of
LRP1 on Aβ metabolism have raised the question to what
extent LRP1 expression affects Aβ pathology in the brain.
APP is a single-pass transmembrane protein, and alternative
splicing of the APP transcript generates many different isoforms
ofwhich three aremost common: the 695 (APP695; predominant-
ly expressed in CNS), the 751 (APP751), and 770 (APP770) ami-
no acid forms [19]. APP isoforms encoding the Kunitz protease
inhibitor domain in their extracellular part (i.e., APP751 and
APP770) interact directly via this domain with a ligand-binding
domain in the extracellular part of LRP1 [13, 14]. The cytoplas-
mic FE65 adaptor protein on the other hand can form a functional
link between the intracellular domains of APP and LRP1 [15].
These interactions between LRP1 and APP allow internalization
of APP into the endosomal compartment. Depending upon rela-
tive expressions levels of LRP1, of the different APP isoforms
and of other involved proteins like FE65, internalization of APP
and subsequent generation of Aβ can be modulated. Upon inter-
nalization of APP, amyloidogenic proteolytic cleavage by beta-
and gamma-secretases results in the generation of Aβ and a
soluble APP-β (sAPP-β) fragment. In contrast, non-
amyloidogenic proteolytic cleavage of APP by alpha-secretase
at the cell surface results in secretion of soluble APP-α (sAPP-α)
and precludes generation of the detrimental Aβ peptide
(reviewed in [5, 20]).
LRP1 is a single-pass transmembrane receptor that binds
over 40 different ligands and is as endocytic and signaling
receptor involved in many different physiological processes
(reviewed in [5, 21]). After proteolytic cleavage of the LRP1
precursor, the mature LRP1 receptor consists of a large extra-
cellular 515-kDa α-subunit (LRP1-α) non-covalently at-
tached to its 85-kDa β-subunit (LRP1-β), consisting of an
extracellular, a transmembrane, and an intracellular domain.
This intracellular domain encodes many motifs, including the
NPxY (xxL) motifs, interacting with adaptor and scaffold pro-
teins. In comparison with the proximal NPxYand distal NPxY
motif (within the NPxYxxL motif) and two di-leucine motifs,
the YxxL motif (within the NPxYxxL motif) is apparently the
predominant internalization motif in LRP1 [22]. Noteworthy
is to mention that FE65 binds to the NPxYxxLmotif to form a
functional link between the intracellular domains of APP and
LRP1, triggering the internalization of the complex and sub-
sequent the generation of Aβ [15]. DAB1, on the other hand,
competes with FE65 for LRP1 binding, resulting in a reduc-
tion of amyloidogenic APP processing [23].
Previously, we reported on the generation of a series of
LRP1 knock-in mice by recombinase-mediated cassette ex-
change [24, 25]. In these mice, the proximal NPxYmotif (also
indicated by NPxY1) and/or the distal NPxYxxL motif (here
indicated by NPxY2) in the intracellular domain are
inactivated. The rationale to generate these mouse models
was to unravel the complex biological function of the receptor
LRP1 by partial impairment of the function of the endogenous
LRP1 receptor. Characterization of the knock-in mouse
models revealed that combined inactivation of the NPxY1
and NPxY2 motifs results in embryonic lethality between
E10.5 and E13.5 reminiscent of the full LRP1 knock-out
[24]. Inactivation of just NPxY1 presents late fetal lethality
due to the impaired early LRP1 biosynthesis, which results in
low levels of mature LRP1 reaching the cell surface [24].
Inactivation of NPxY2 (simultaneous inactivation of the over-
lapping NPxY and YxxL motifs) was initially not linked to a
clear phenotype [25], but in a LDLR-deficient mouse model,
inactivation of NPxY2 enhances postprandial dyslipidemia
and atherosclerosis demonstrating that NPxY2 is essential
for the atheroprotective role of LRP1 [26]. Furthermore,
NPxY2 inactivation was shown in vitro in mouse-derived
cells to compromise LRP1 endocytosis rates of ApoE, α2M
and NR2B NMDA receptor subtype, and β1-integrin [24,
27–29]. This is mainly a consequence of inefficient slow
recycling of the mutated receptor [27]. We also identified the
NPxY2 motif of LRP1 as a crucial element for LRP1-NMDA
receptor interaction via the adaptor protein PSD95 and rele-
vant for tPA activation of the LRP1-NMDA receptor complex
in derived neuronal cells [30]. Finally, inactivation of NPxY2
resulted in impairment of transcytosis of Aβ1–40 across a
brain endothelial monolayer [10].
In the current study, we sought to study the dual role of LRP1
on Aβ metabolism in vivo. We report on the in vivo impact of
the LRP1-inactivating NPxY2 mutation on APP processing in a
mouse model overexpressing human APP. Our results provide
the first in vivo evidence that in accordance with the cellular
in vitro models, endogenous LRP1 contributes to the generation
of Aβ and simultaneously is a receptor for Aβ clearance. A loss
of LRP1 function results in a reduction of Aβ clearance, but at
the same time favors non-amyloidogenic APP processing, reduc-
ing the overall generation of Aβ and leading to a diminished Aβ
pathology in brain.
Methods
Mice
Generation of a LRP1-NPxY2 mutant knock-in mouse with
i n a c t i v a t i o n o f t h e memb r a n e d i s t a l NPxY2
(NPVYATL ➔ AAVAATL) motif was already described in
detail before [25]. For analysis of the in vivo effect of
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inactivation of the membrane distal NPxY2 motif on the APP
metabolism in a AD mouse model, LRP1-NPxY2 mutant
mice were crossed with the Thy1-hAPP751SL AD mouse
model described by Blanchard et al. [31], overexpressing a
human APP751 isoform carrying the Swedish and London
mutations. Breeding pairs of heterozygous LRP1-NPxY2 mu-
tant knock-in mice of which the male or female was addition-
ally carrying the Thy1-hAPP751SL transgene were used to
generate inbred LRP1 wildtype mice and homozygous
LRP1-NPxY2 mutant knock-in mice, without or hemizygous
for the Thy1-hAPP751SL transgene (mixed C57Bl/6J and 129
background). Unless otherwise stated, female mice of an age
of 9 months were analyzed in a comparative study. For in vitro
endothelial transcytosis analysis, inducible brain endothelial-
specific LRP1 knock-out mice (Lrp1BE
−/−) were used as de-
scribed in detail before [12]. The research was approved by
the Ethical Committees for Animal Experimentation of the
KU Leuven and the Johannes Gutenberg University of
Mainz and the ethical committee on animal care and use of
Rhineland-Palatinate, Germany.
Isolation of Total Protein Homogenates and Protein
Fractionation from Mice Brains
Mice, euthanized by CO2 intoxication or pentobarbital
(100 mg/kg, i.p.), were perfused transcardically with PBS.
After isolations of the brains, hemispheres were snap-frozen
in liquid nitrogen and stored at − 80 °C until further process-
ing. For the analysis of APP metabolism in protein
subfractions, 6-ml ice-cold buffer [20-mM Tris-HCl, 1× com-
plete proteinase cocktail (Roche) (pH 8.5)] per gram frozen
tissue was used for homogenization with a cooled glass-
Teflon Potter-Elvehjem type of homogenizer (18 strokes,
350 rpm). Total protein homogenates were obtained after brief
centrifugation (12,000 g, 15 min, 4 °C) to remove debris.
Small aliquots of the total protein homogenates were stored
at − 20 °C, whereas the remaining large aliquots were used
according to a differential extraction procedure to obtain frac-
tions containing soluble proteins, TX100-soluble membrane
proteins, and insoluble or Bplaques^-associated proteins as
described before with minor modifications [32]. After an ini-
tial centrifugation step (100,000 ×g for 80 min at 4 °C,
Beckman TL100), the supernatant was collected as soluble
protein fraction, whereas the pellet fraction was resuspended
in 6-ml ice-cold buffer supplemented with 1% TX100 per
gram pellet fraction. After a next centrifugation step
(100,000 ×g for 80 min at 4 °C, Beckman TL100), the super-
natant was collected as the TX100-soluble membrane protein
fraction. All fractions were stored at − 20 °C until analysis.
For analysis of the different Aβ species in PBS-soluble pro-
tein fractions by a combination of immunoprecipitation and
western blot analysis, a different fractionation protocol was
used [12]. Briefly, brain hemispheres were homogenized in
1000-μL PBS containing complete protease and phosphatase
inhibitor (Roche Applied Science) using a glass homogenizer
(30 strokes) and subsequently centrifuged at 55,000 g for
20 min at 4 °C. The supernatant containing secreted PBS-
soluble brain Aβ was collected and stored at − 20 °C for
further analysis.
Western Blot Analysis of APP and APP Metabolites
and ELISA for Aβ
Protein concentrations of the soluble protein fractions and of
the TX100-soluble membrane protein fractions were deter-
mined by the bicinchoninic acid assay kit (PIERCE, Perbio,
France), and samples containing 10-μg protein were prepared
in LDS sample buffer (Invitrogen NP-009). After reduction
and denaturation at 95 °C for 10 min, the samples were loaded
and separated by PAGE on 4–20% or 10% Tris-glycine
(Anamed, Germany) and transferred onto nitrocellulose mem-
branes. Ponceau S (Sigma-Aldrich) was used to confirm load-
ing of equal amounts of protein and to monitor the transfer
procedure. After blocking with blocking buffer [TBS (50-mM
Tris, 150-mM NaCl, pH 7.6) containing 0.1% Tween 20 and
5%milk], the membranes were probed overnight (4 °C) with a
primary antibody diluted in blocking buffer. Membranes were
rinsed in TBS containing 0.1% Tween 20 and incubated with
appropriate horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies diluted in blocking buffer. Careful execu-
tion of the homogenization and fractionation procedures in
combination with the Ponceau S staining of the blots con-
firmed loading and subsequent transfer of equal amounts of
protein in the analyzed protein fractions (see Supplementary
Fig. 1a, Supplementary Fig. 2a, b). In the case of western blot
analysis of total homogenates, usually, normalization of west-
ern blot expression levels to housekeeping genes, like actin or
tubulin, is done. At first sight, use of analysis of actin expres-
sion in combination with a fractionation procedure following
upon homogenization appears less suitable, but in our frac-
tionation procedure the distribution of actin between the sol-
uble protein fraction and TX100-soluble membrane protein
fractions was shown to occur according a relatively stable
and reproducible ratio (see Supplementary Fig. 1b),
confirming also in this way loading and transfer of equal
amount of protein in the analyzed protein fractions.
Moreover, we analyzed up to n = 5–6 animals per group to
get representative results.
For detection of immature and mature APP in the TX100-
soluble membrane protein fraction, the primary rabbit polyclon-
al antibody B10.4 (homemade, directed against the 20 carboxy-
terminal amino acids of APP) was used. For detection of total
sAPP and sAPP-α in the soluble protein fraction, the primary
mouse monoclonal antibodies 22C11 (Chemicon, directed
against aa 6–81 of APP) and 6E10 (Chemicon, directed against
aa 1–17 of Aβ) were used respectively. For detection of
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sAPP-β in the soluble protein fraction, a rabbit antibody
(Signet, 9138-005) was used. Mouse anti-tubulin (T8328,
Sigma-Aldrich), mouse anti-synaptophysin (101011, Synaptic
Systems), and mouse anti-PSD-95 (P43520, BD Transduction
Laboratories) were used to control for equal loading of mem-
brane fractions. Finally, mouse monoclonal anti-β-actin clone
AC-15 (Sigma-Aldrich) was used for analysis of actin expres-
sion. Secondary antibodies were conjugated with HRP.Western
blots were developed by chemiluminescence (Western
Lightning ECL Pro; Perkin-Elmer) followed by digital picture
acquisition and analysis (LAS 4000; ImageQuant v7.0; GE
Healthcare). Final blot pictures were equally adjusted to en-
hance visibility using Adobe Photoshop (version 7.0) (Adobe
Systems, San Jose, USA).
Immunoprecipitation of Total Aβ from PBS-Soluble
Protein Fractions and Subsequent Aβ Separation
with 8-M Urea SDS Gel and Western Blotting
Total Aβ was immunoprecipitated from 1000-μg protein of
PBS-soluble protein fractions bymixing fivefold concentrated
detergent buffer [50-mM HEPES (pH 7.4), 150-mM NaCl,
0.5% (v/v) Nonidet P-40, 0.05% (w/v) SDS, and protease in-
hibitor cocktail (Roche Applied Science)] with the respective
samples. Magnetic Dynabeads (M-280 Sheep Anti-Mouse
IgG, 11201D, Novex) containing sheep anti-mouse IgG at-
tached to their surface were precoated with IC16 antibody
directed against the first 16 amino acids of Aβ [33] according
to the manufacturer’s protocols, and equal amounts of IC16
antibody-covered beads were added to the samples as shown
by the immunoreactivity of IC16 light chain displayed in
Supplementary Fig. 3. After overnight incubation at 4 °C,
samples were washed 3 times in PBS, 0.1% (w/v) BSA, and
once in 10-mMTris-HCl, pH 7.5. After heating the samples to
95 °C in 25-μl sample buffer [0.36-MBis-Tris, 0.16-M bicine,
1% (w/v) SDS, 15% (w/v) sucrose, and 0.0075% (w/v)
bromphenol blue], the supernatants were subjected to PAGE.
Separation of immunoprecipitated Aβ peptides was per-
formed on 0.75-mm 10% T/5% C polyacrylamide 8-M urea
SDS gels. For separation of Aβ1–40 from Aβ1–42, a final
concentration of 0.3-M H2SO4 was used in resolving gels.
This has the effect that peptides are separated not only accord-
ing to their molecular weight but also according to their hy-
drophobicity and results that Aβ1–42 migrates faster than
Aβ1–40. Peptides were transferred to an Immobilion-P
PVDF membrane via semi-dry western blotting (Bio-Rad) at
46 mA for 45 min. Membranes were boiled for 3 min in PBS
and blocked in 5% skimmilk in TBST [20-mMTris, 137-mM
NaCl, 0.1% (v/v) Tween-20] for 30 min afterward. Aβ pep-
tides were detected with IC16 antibody and donkey anti-
mouse second antibody conjugated with HRP using enhanced
chemiluminescence (Millipore, Schwalbach, Germany) and
digital picture acquisition (LAS-3000mini, Fujifilm,
Duesseldorf, Germany).
Isolation of Cerebrospinal Fluid for Aβ ELISA
For isolation of CSF from the cisterna magna, the method
previously described by DeMattos was used [34].
Subsequently, the Aβ40 and Aβ42 levels in the CSF were
determined by Aβ40 and Aβ42 specific ELISA kits, accord-
ing to the manufacturer’s instructions (the Genetics
Company).
Isolation and Culture of Primary Mouse Brain
Capillary Endothelial Cells
Primary mouse brain capillary endothelial cells were isolated
from 12- to 15-week-old mice according to a standard proto-
col as described previously [10, 35]. Cells were plated on 24-
well Transwell filters (pore size, 0.4 μm; surface area,
33.6 mm2; Greiner Bio-One) coated with collagen IV/
fibronectin (Sigma-Aldrich). Cultures were maintained in
DMEM supplemented with 20% plasma-derived bovine se-
rum (First Link), 100-U/ml penicillin (Gibco), 100-μg/ml
streptomycin (Gibco), 2-mM L-glutamine (Gibco), 4-μg/ml
puromycin (Alexis), and endothelial cell growth supplement
(E2759, Sigma) at 37 °C and 5% CO2. Cells were cultured in
the cellZscope device, in which transendothelial electrical re-
sistance (TEER) and capacitance were monitored over time.
Puromycin was withdrawn after 4 days in culture. When cells
reached confluency and the capacitance was around 1 μF/cm2,
culture medium was removed, and serum-free DMEM/Ham’s
F12 (Gibco) medium containing 1-mM L-glutamine, 100-U/
ml penicillin, and 100-μg/ml streptomycin was added. Five
hundred fifty nM hydrocortisone (Sigma-Aldrich) was sup-
plemented to induce high TEER. The following day transport
studies were performed.
In Vitro Transcytosis of [125I]-Aβ1–42
In order to study Aβ transcytosis in vitro, a standard transport
model was used [10, 12, 35]. [125I]-Aβ1–42 (0.1 nM) (pur-
chased from Phoenix Peptide) and 1-μCi/ml [14C] inulin (pur-
chased from PerkinElmer), a marker for paracellular diffusion,
were added to serum-free media supplemented with 550-nM
hydrocortisone and 40-mM HEPES and incubated at 37 °C.
To study brain-to-blood transport, 10- and 80-μl samples were
taken from the luminal compartment 60 min after the addition
of [125I]-Aβ1–42 and [14C]-inulin to the abluminal compart-
ment. To investigate the amount of intact [125I]-Aβ1–42
transported to the luminal side, 80-μl 15% TCA was added
to an 80-μl luminal media sample and incubated for 10 min at
4 °C. Samples were then centrifuged at 16,000 g for 10 min.
Pellets (representing intact [125I]-Aβ1–42) were counted for
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[125I]. Probes were counted on a Wallac Wizard2 2470 auto-
matic γ-counter (PerkinElmer) for [125I] or on a Tri-Carb 2800
TR Liquid Scintillation Analyzer (PerkinElmer) for [14C].
Transport of intact [125I]-Aβ1–42 across the monolayer was
calculated as Aβ1–42 transcytosis quotient (TQ) using the
following formula:
Aβ1−42 TQ ¼ 125I −Aβ1−42 luminal= 125I −Aβ1−42 input =
14C
 
−inulin acceptor= 14C
 
−inulin input
 
Brain Clearance of [125I]-Aβ1–42
To measure the brain clearance of [125I]-Aβ1–42, we used a
similar method as described previously [12]. 0.5-μl tracer flu-
id containing 1 μCi/ml [14C]-inulin (reference marker) and
pathophysiological amounts of [125I]-Aβ1–42 (5.14 nM)
was injected with a 26-gauge needle attached to an
UltraMicroPump controller (UMP3-1, Word Precision
Instruments) over 5 min into ISF of the right caudate putamen
(0.9 mm anterior from bregma, 1.9 mm lateral from midline,
and 2.9 mm below the surface) of 4 months old and sex-
matched mice anesthetized with ketamine (800 mg/kg) and
medetomidine (5 mg/kg). After injection, the microsyringe
was left in place for 5 min. Blinded brain samples were col-
lected at 10 min after injection and prepared for analysis.
In vivo [125I]-Aβ1–42 clearance was calculated as follows:
100% recovery in brain after 15 min. The percentage of radio-
activity remaining in the brain was calculated as follows: %
recovery in brain = 100 × (Nb / Ni), where Nb is the radioactiv-
ity in the brain at the end of the experiment and Ni is the
radioactivity injected into the brain, as illustrated by TCA-
precipitable [125I]-radioactivity (measured in cpm).
Immunohistochemistry
Mice, euthanized by CO2 intoxication, were perfused
transcardically with PBS followed by a 4% paraformaldehyde
(PFH) solution in phosphate-buffered saline (PBS). After iso-
lation of the brains, brains were postfixated overnight in 4%
PFH in PBS and finally rinsed in PBS. The brains were then
dehydrated and embedded in paraffin for sectioning (7 μm in
thickness). Paraffin-embedded brain sections were dewaxed
and rehydrated, the epitope was exposed in 1/3 formic acid
for 7 min, and endogenous peroxidase was quenched with
hydrogen peroxide [3% (v/v) in methanol] for 10 min. After
sufficient washing with PBS, slides were incubated for 5 min
in PBS supplemented with 1% Tween 20 followed by 2 h in a
blocking buffer [5% goat normal serum, 2% BSA, 0.5%
blocking reagent (Perkin Elmer), 10-mM Tris-HCl, 150-mM
NaCl, pH 7.5]. The primary antibody diluted in blocking buff-
er was applied overnight at 4 °C. Following sufficient
washing, secondary antibody diluted in blocking buffer was
applied for 2 h at RT. For analysis of the plaque load, primary
mouse monoclonal antibody 6E10 (Chemicon, directed
against amino acids 1–17 of Aβ) and secondary antibody
GAM-HRP were used, and the signal was visualized with
the TSA™ PLUS kit from Perkin Elmer according to the
manufacturer’s instructions. Photographs were taken with a
Leica MZ FLIII stereomicroscope. The number of plaques
and the percentage of the brain covered with plaques was
analyzed by ImageJ 1.41 software from the National
Institute of Health (NIH) on four consecutive sections from
each mouse around bregma − 2.5.
Statistical Analysis
Statistical significance was assessed using Student’s t test.
Whenever necessary, data were logarithmically transformed
to meet t test assumptions. p < 0.05 was regarded statistically
significant.
Results
Decreased Brain Clearance of Aβ in Mice Carrying
the NPxY2 Knock-in Mutation
Previously, we have shown that primary endothelial cells de-
rived from LRP1NPxY2/NPxY2 mice show reduced transport of
Aβ across the endothelial cells compared with those from
LRP1WT/WT mice, corroborating that LRP1 is an important
clearance receptor for neurotoxic Aβ from brain [9, 10]. In
our present analysis, we verified our original findings (Fig. 1a,
b), showing that transcytosis of Aβ1–42 was reduced in en-
dothelial cells carrying the LRP1 NPxY2 knock-in mutation
compared to wild-type (wt) endothelial cells. The reduction in
transport we observed was comparable to endothelial cells
deficient of LRP1 (KO) implicating that Aβ transport capacity
is highly impaired by the NPxY2 knock-in mutation [12].
These data again demonstrated that on a cellular level, im-
paired LRP1 function due to its decreased internalization leads
to decreased Aβ clearance. LRP1 expression is not restricted
to cells compromising the BBB. In fact, it has been shown that
also neuronal, astrocytic LRP1, and also LRP1 in smooth
muscle cells contribute to the clearance of Aβ in vivo [6, 7,
36]. In order to study total brain clearance in vivo, we injected
radiolabelled [125I]-Aβ1–42 into the caudate putamen of
LRP1NPxY2/NPxY2 and LRP1WT/WT mice (Fig. 1c). Whereas
Aβ was rapidly cleared from brain in LRP1WT/WT mice,
LRP1NPxY2/NPxY2 showed a significant impairment in Aβ
clearance from brain (Fig. 1d). Together, these results demon-
strated that not only on a cellular level but also in vivo
LRP1NPxY2/NPxY2 mice show a reduction in the capacity of
Aβ clearance.
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As we saw that NPxY2-mutated LRP1 showed a reduction
in Aβ clearance in vitro and in vivo, we crossed LRP1NPxY2/
NPxY2 mice with Thy1-hAPP751SL mouse model that ex-
presses human APP bearing both the Swedish (K670N/
M671L) and the London (V717I) mutations (LRP1NPxY2/
NPxY2/hAPP751SL). We analyzed the CSF of 9-month-old
mice by Aβ ELISA measures. Interestingly, we found that
CSF concentrations of both Aβ40 and Aβ42 in LRP1NPxY2/
NPxY2/hAPP751SL were significantly lower than in LRP1
WT/
WT/hAPP751SL control mice (Fig. 2a). This finding seemed to
contradict our original idea that Aβ should accumulate due to
impaired brain clearance. Moreover, we analyzed the soluble
levels of Aβ in the brain by homogenizing the brain hemi-
spheres in PBS followed by immunoprecipitation.
Corresponding to what we saw in the CSF, we found
significantly lower Aβ1–40 and Aβ1–42 levels in the PBS-
soluble fraction of the brain as analyzed by SDS-urea gel
electrophoresis (Fig. 2b). Although several measures showed
lower Aβ levels in fluids of the CNS in mice with impaired
LRP1 function, it seemed to contradict all findings from pre-
vious studies showing that LRP1 impairment results in the
accumulation of Aβ due to impaired clearance [11, 12, 37].
Next, we analyzed APP expression in brains of
LRP1NPxY2/NPxY2/hAPP751SL and LRP1
WT/WT/hAPP751SL
controls with western blot analysis after protein fractionation.
Loading and subsequent transfer of equal amounts of protein
in the analyzed protein fractions were confirmed by Ponceau S
staining and analysis of the expression of actin, which was
apparently distributed according to a reproducible and stable
ratio between the soluble protein fractions and TX100-soluble
Fig. 1 Decreased Aβ brain clearance and endothelial transcytosis in
LRP1 NPxY2 mice. a Diagram illustrating the experimental procedure
of [125I]-Aβ1–42 transport across the primary mouse brain capillary
endothelial cell monolayer cultured on Transwell inserts. b [125I]-Aβ1–
42 transport across the primary mouse brain capillary endothelial cell
monolayer derived from control LRP1WT/WT (WT), LRP1BE
−/− (brain
endothelial-specific knock-out, KO), and LRP1NPxY2/NPxY2 (NPxY2)
mice was studied in the presence of 1-μCi/ml [14C]-inulin to determine
the transcytosis quotient (TQ). Transcytosis was analyzed in the brain-to-
blood direction (abluminal to luminal) by measuring the dpm for [14C]-
inulin and the cpm for the TCA-precipitable [125I] radioactivity. Data of
three independent experiments, n = 22 (WT), n = 12 (KO), and n = 17
(NPxY2) (age 12–15 weeks). c Diagram illustrating the experimental
procedure of in vivo brain clearance in mice. d LRP1 NPxY2 knock-in
mutation inhibits Aβ brain clearance in vivo in LRP1NPxY2/NPxY2
(NPxY2) mice compared with control LRP1WT/WT (WT) mice. 5.14-
nM [125I]-Aβ1–42 was microinfused into brain ISF of the caudate
nucleus. Efflux was studied 15 min after injection by determining
remaining radioactivity in the brain. n = 4 (WT and NPxY2, age
4 months). Error bars represent SEM. For statistical analyses of the data
in B, the following test was used: repeated-measures ANOVA followed
by Bonferroni multiple comparisons. For statistical analyses of the data in
d, Student’s t test was used. * indicates p < 0.05, *** indicates p < 0.001
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membrane protein fractions (see Supplementary Fig. 1a, b).
Additionally, we analyzed membrane proteins PSD-95 and
synaptophysin as an internal control for equal loading of
membrane fractions (see Supplementary Fig. 2a, b). We could
not see any effects on the total mature an immature forms of
APP in the TX100-soluble membrane protein fraction
(Fig. 3a), indicating that no differences in APP expression
are the reason for the reduced levels of Aβ found in CSF
and PBS-soluble fractions. Analysis of the soluble protein
fraction, however, showed that of LRP1NPxY2/NPxY2/
hAPP751SL exhibited in significant increase of total sAPP
and sAPP-α levels (Fig. 3b), suggesting that APP processing
is altered in these mice. Vice versa, we could detect a trend
towards lower sAPP-β levels that did not reach statistical
significance (Fig. 3b).
The evident increase in sAPP-α and reduction in soluble
total Aβ indicated that inactivation of LRP1 through its
NPxY2 knock-in mutation shifts APP from amyloidogenic
by beta-secratase to non-amyloidogenic processing by alpha-
secretase at the cell surface, presumably due to impaired APP
endocytosis by LRP1.
Inactivation of the NPxY2 Motif Is Associated
with a Reduced Aβ Plaque Load in Brains of APP751SL
Mice
As our findings suggested that reduced endocytosis of APP by
the impaired function of LRP1 promotes APP processing by
alpha-secretase and thus lowering the generation of Aβ, we
analyzed the plaque deposition in aged mice overexpressing
human APP (hAPP751SL). Female mice were used, because
they show an earlier phenotype than males.
Brain sections of 9-month-old female LRP1WT/WT/
hAPP751SL and LRP1
NPxY2/NPxY2/hAPP751SL mice were im-
munostained for Aβ (6E10 antibody) to visualize plaques.
Analyses of four consecutive brain slices confirmed that the
total number of plaques in the brain (Fig. 4a, b) as well as the
percentage of the brain covered with plaques (Fig. 4a, c) was
significantly reduced by 36 and 38% in the LRP1NPxY2/NPxY2/
hAPP751SL mice when compared with the LRP1
WT/WT/
hAPP751SL controls. Therefore, inactivation of LRP1 does
not only affect the soluble brain levels of Aβ but also influ-
ence its plaque deposition despite impaired Aβ clearance of
LRP1.
Discussion
The objective of the present study was to investigate in vivo
the impact of impaired LRP1 function on the APP processing.
Previously, it has been shown that inactivation of the NPxY2
motif of endogenous LRP1 results in a partial inhibition of the
endocytosis (and transcytosis in brain endothelial cells) of
ligands or complexes with co-receptors by this LRP1 receptor
[10, 24, 26–30]. In the present study, we could confirm that
impairment of LRP1 endocytosis inhibits the brain clearance
of Aβ in vitro and in vivo. At the same time, we found that
impairment of LRP1 endocytosis influences the overall gen-
eration of Aβ by promoting alpha-secretase cleavage at the
cell surface (as seen by higher sAPP-α levels) and the preven-
tion of Aβ generation after endocytosis in vivo. Interestingly,
our collective results suggest that despite impaired Aβ brain
clearance due to the inactivation of LRP1, there is less accu-
mulation of Aβ in CSF, ISF, and in plaques in a mouse model
of AD in vivo.
This study clearly demonstrates that LRP1 has a dual
role APP metabolism affecting both generation and clear-
ance of Aβ. Many studies have shown both in vitro and
Fig. 2 Decreased levels of Aβ in brain fluids of LRP1 NPxY2 mice. a
ELISA on CSF obtained from the cisterna magna showed significant
reduced levels for Aβ40 and Aβ42 in LRP1NPxY2/NPxY2/hAPP751SL
(NPxY2 + APP) mice compared with LRP1WT/WT/hAPP751SL (WT +
APP) mice. n = 10 for both groups (age 9 months). b WB analysis of
the PBS-soluble protein fractions showed significant reductions in total
Aβ, Aβ1–42, and Aβ1–40 levels in the NPxY2 +APPmice compared to
control WT +APP. n = 5 (WT +APP) and n = 6 (NPxY2 + APP) (age
9 months). Error bars represent SEM, and statistical analysis was
performed with Student’s t test, * indicates p < 0.05
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in vivo that LRP1 is an important mediator in the clear-
ance of Aβ from the brain, e.g., in receptor-mediated en-
docytosis in astrocytes, neurons, and cerebrovascular
smooth muscle cells [6–8]; in transcytosis across the
BBB [9–12]. Cell type-specific deletion of LRP1 in astro-
cytes, neurons, smooth muscle cells, and endothelial cells
has all led to a general increase of brain Aβ. Studies on
the general impact of LRP1 in different cell types on Aβ
metabolism or its effect on APP processing, and thus, the
generation of Aβ in vivo is scarce. Many in vitro studies
support a role for LRP1 in the generation of Aβ [13–18].
However, direct in vivo support for the involvement of
LRP1 is limited. It has been shown that overexpression
of a functional LRP1 mini-receptor in an APP transgenic
mouse model [38] resulted in an age-dependent increase
of soluble brain Aβ [39]. These observations in this over-
expressing mouse model support our findings and LRP1’s
role in amyloidogenic processing of APP in vivo. This
study, for the first time, has modulated endogenous and
global LRP1 function and has studied the effect on Aβ
metabolism. Overall inhibition of endogenous LRP1 is
expected to simultaneously affect generation and
Fig. 3 No difference in APP
expression but difference in sAPP
shedding in LRP1 NPxY2 knock-
in mice. a WB analysis of the
TX100-soluble membrane protein
fractions showed no differences in
the expression levels of
unprocessed full length immature
and mature APP in brains of
LRP1NPxY2/NPxY2/hAPP751SL
(NPxY2 +APP) mice compared
with control LRP1WT/WT/
hAPP751SL (WT +APP) mice. b
WB analysis of the soluble
protein fractions revealed a
significant increase of total sAPP
and sAPP-α in LRP1NPxY2/NPxY2/
hAPP751SL (NPxY2 +APP)mice
compared with control LRP1WT/
WT/hAPP751SL (WT +APP)
mice. The trend in reduction in
sAPP-β did not reach statistical
significance. Number of mice
analyzed: n = 6 mice (WT +APP)
and 5–6 (NPxY2 +APP) (age
9 months). Error bars represent
SEM, and statistical analysis was
performed with Student’s t test, *
indicates p < 0.05
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clearance of Aβ, in which opposing effects could mask
each other. In our present study, we see both: due to LRP1
inactivation in vivo brain clearance and, at the same time,
the generation of Aβ is impaired. Still, the net effect of
impaired LRP1 function on brain Aβ, despite its impaired
clearance, is a lesser accumulation of Aβ in the brain.
Thus, the present results are a direct in vivo support that LRP1
is involved in amyloidogenic APP processing. Hence, the recep-
tor that is involved in the generation of potentially toxic Aβ
through receptor-mediated endocytosis of APP, at the same time,
keeps soluble brain Aβ low by the constant clearance of Aβ
from ISF and CSF through endocytosis and subsequent degra-
dation or transcytosis across the BBB (see Fig. 5). The clearance
function of LRP1 in the different cells of the brain seems crucial
as multiple cell-specific knock-out mouse models have shown
that LRP1 ablation leads to a net accumulation of Aβ in the
brain. One has to say that this carefully balanced system of Aβ
production and clearance is influenced not only by LRP1 expres-
sion itself but also by other members of the LDLR family that
modulate APP endocytosis (reviewed in [40]). Therefore, chang-
es in expression of different LDLR family members will modu-
late the generation versus clearance machinery. However, our
study concentrating on LPR1 function on APP metabolism
in vivo suggests that LRP1 is actually promoting the generation
of Aβ, while at the same time preventing its accumulation by
mediating its clearance.
It is noteworthy to say that it is most likely not feasible to
target LRP1 expression in the brain to reduce the production of
Aβ: LRP1 has numerous other functions besides mediating en-
docytosis. Over the years, studies have shown that LRP1 is in-
volved in many important cellular processes, including cell sig-
naling, cell migration, proliferation, angiogenesis, and wnt sig-
naling modulation ([41], reviewed in [42]). Embryonic lethality
of global LRP1 knock-out mice shows the importance of the
receptor in these processes during development. On the other
hand, cell-specific LRP1 knock-out mouse models have shown
that clearance ofAβ can bemodulated by LRP1 expression [6, 7,
12, 36]. As it is unlikely that we can control LRP1-mediated
production of Aβ, future therapeutic approaches should concen-
trate on enhancing LRP1-mediated Aβ clearance from the brain.
In conclusion, our findings for the first time show that endog-
enous LRP1 has a predominate role in regulating the processing
of APP in vivo. Our analysis in amousemodel of AD shows that
impairment of LRP1 inhibits Aβ brain clearance but simulta-
neously reduces its production resulting in an overall reduced
Aβ pathology in the brain and therefore gives important insights
in the molecular mechanisms underlying metabolism of Aβ
in vivo.
Fig. 4 Plaque load in brain is
significantly reduced in LRP1
NPxY2 mice. a Brain slices
(bregma − 2.5) of LRP1WT/WT/
hAPP751SL (WT +APP) and
LRP1NPxY2/NPxY2/hAPP751SL
(NPxY2 +APP) mice were
immunostained with the antibody
6E10, and plaques were
visualized with the TSA™PLUS
kit from Perkin Elmer. Pictures
show representative stainings for
WT +APP and NPxY2 +APP
mice. b The number of plaques as
determined in 6E10-
immunostained brain slices via
ImageJ software from NIH. c The
percentage of the brain covered
with plaques as determined in
6E10-immunostained brain slices
via ImageJ software from NIH.
For b and c, n = 10 for LRP1WT/
WT/hAPP751SL (WT +APP) mice
and n = 8 for and LRP1NPxY2/
NPxY2/hAPP751SL (NPxY2 +
APP) mice (age 9 months). Error
bars represent SEM, and
statistical analysis was performed
with Student’s t test, * indicates
p < 0.05
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